AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CYNATA THERAPEUTICS LTD

0.012

+0.0019.09%

Volume:881.91K

Turnover:10.12K

Market Cap:2.92M

PE:-0.33

High:0.012

Open:0.011

Low:0.011

Close:0.011

52wk High:0.435

52wk Low:0.011

Shares:243.45M

Float Shares:175.62M

Volume Ratio:2.80

T/O Rate:0.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.037

EPS(LYR):-0.046

ROE:-112.99%

ROA:-62.05%

PB:0.86

PE(LYR):-0.26

Loading ...

Overview Company News Filings

Cynata Therapeutics Makes All Employee Positions Redundant Including CEO and MD

Cynata Therapeutics Ltd-final Director's Interest Notice

THOMSON REUTERS

Cynata Therapeutics - Makes All Employee Positions Redundant Including CEO and Md Effective 6 July 2026

THOMSON REUTERS

Cynata Therapeutics Ltd-board, Management Changes, Expenditure Reductions, Rdti Loan

THOMSON REUTERS

Cynata Therapeutics' Failure to Meet Main Endpoints in Two Trials is 'Highly Disappointing Outcome,' Euroz Hartleys Says

MT Newswires Live

Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results

MT Newswires Live

BRIEF-Cynata Therapeutics Seeks Trading Halt

Cynata Therapeutics - Trading Halt Pending Phase 3 Osteoarthritis and Phase 2 Gvhd Trial Results

THOMSON REUTERS

Cynata Therapeutics Gets Positive European Opinion for Acute Graft Versus Host Disease Trial

MT Newswires Live

Cynata Says WHO Selects Generic Name for Cymerus Mesenchymal Stem Cells

MT Newswires Live

Cynata Therapeutics Ltd-Who Selects Proposed Inn for Cymerus Mscs

THOMSON REUTERS

Cynata Therapeutics Says Results for Phase Three Drug Candidate Study for Knee Osteoarthritis Expected in June; Shares Rise 6%

MT Newswires Live

Cynata Therapeutics' Upcoming Trial Readouts 'Most Significant Catalysts' in Years, Euroz Hartleys Says

MT Newswires Live

Cynata Therapeutics Secures Commitments for AU$1.5 Million Share Placement; Shares Fall 4%

MT Newswires Live

BRIEF-Cynata Therapeutics Receives Commitments For A$1.5 Mln Placement At A$0.25 Per Share

Cynata Therapeutics Ltd - Receives Commitments for a$1.5 Mln Institutional Placement at a$0.25 per Share

THOMSON REUTERS

BRIEF-Cynata Therapeutics Seeks Trading Halt Pending Announcement On Proposed Capital Raising

Cynata Therapeutics Ltd - Trading Halt Requested Pending Announcement on Proposed Capital Raising via Share Placement

THOMSON REUTERS

Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period

MT Newswires Live

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CYP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","market":"AU","secType":"STK","nameCN":"CYNATA THERAPEUTICS LTD","latestPrice":0.012,"timestamp":1787292720000,"preClose":0.011,"halted":0,"volume":881913,"delay":0,"changeRate":0.090909090909091,"nameEN":"CYNATA THERAPEUTICS LTD","floatShares":175624818,"shares":243454369,"eps":-0.036606,"marketStatus":"Market Closed","change":0.001,"latestTime":"08-21 16:12:00 AEST","open":0.011,"high":0.012,"low":0.011,"amount":10123,"amplitude":0.090909,"askPrice":0.012,"askSize":8284,"bidPrice":0.011,"bidSize":1180055,"shortable":3,"etf":0,"ttmEps":-0.036606,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":2.801984966560064,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CYP.AU","preClose":0.011,"auctionPrice":0.012,"auctionVolume":216,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292007381}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","floatShares":175624818,"roa":"-62.05%","roe":"-112.99%","lyrEps":-0.045818,"volumeRatio":2.801984966560064,"shares":243454369,"dividePrice":0,"high":0.012,"amplitude":0.090909,"preClose":0.011,"low":0.011,"week52Low":0.011,"pbRate":"0.86","psRate":"1.73","week52High":0.435,"institutionHeld":0,"latestPrice":0.012,"committee":0.986058,"eps":-0.036606,"divideRate":0,"volume":881913,"delay":0,"ttmEps":-0.036606,"open":0.011,"prevYearClose":0.345,"prevWeekClose":0.011,"prevMonthClose":0.012,"prevQuarterClose":0.014,"fiveDayClose":0.011,"twentyDayClose":0.012,"sixtyDayClose":0.255,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-12-15","symbol":"CYP.AU","defaultRemindTime":1607986800000,"type":"split","dateTimestamp":1607950800000,"forFactor":2147483647,"toFactor":2147483647,"ratio":0.997023}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649827617","title":"Cynata Therapeutics Makes All Employee Positions Redundant Including CEO and MD","url":"https://stock-news.laohu8.com/highlight/detail?id=2649827617","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649827617?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:47","pubTimestamp":1783302460,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Makes All Employee Positions Redundant Including CEO And MDJuly 6 -Cynata Therapeutics LtdCYP.AX:BOARD, MANAGEMENT CHANGES, EXPENDITURE REDUCTIONS, RDTI LOANMAKES ALL EMPLOYEE POSITIONS REDUNDANT INCLUDING CEO AND MD EFFECTIVE 6 JULY 2026Further company coverage:CYP.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUE785S0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CYP.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649691611","title":"Cynata Therapeutics Ltd-final Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2649691611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649691611?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:37","pubTimestamp":1783291072,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE7PX0ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649664611","title":"Cynata Therapeutics - Makes All Employee Positions Redundant Including CEO and Md Effective 6 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649664611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649664611?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:35","pubTimestamp":1783290907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE785S0X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CYP.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649261166","title":"Cynata Therapeutics Ltd-board, Management Changes, Expenditure Reductions, Rdti Loan","url":"https://stock-news.laohu8.com/highlight/detail?id=2649261166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649261166?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:35","pubTimestamp":1783290907,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE785S0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CYP.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644305396","title":"Cynata Therapeutics' Failure to Meet Main Endpoints in Two Trials is 'Highly Disappointing Outcome,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644305396","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644305396?lang=en_us&edition=fundamental","pubTime":"2026-06-19 13:53","pubTimestamp":1781848436,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  failed to meet the primary endpoints of a phase 3 osteoarthritis trial and a phase 2 graft-versus-host disease study, representing \"a highly disappointing outcome,\" Euroz Hartleys said in a Friday report.The phase 2 results, which showed a lack of efficacy across both the primary and secondary endpoints, are surprising as the earlier phase 1 graft-versus-host disease trial generated encouraging results, the investment firm said.Following Cynata's decision to discontinue the phase 2 study, the equity research firm considers the company's graft-versus-host disease program to be effectively discontinued in its current form.Meanwhile, the phase 3 osteoarthritis trial appears to have been impacted by a stronger-than-anticipated placebo response, as the 48.1% response rate to the patient-acceptable symptom state pain threshold in the control group was much higher than the 35% rate assumed in the study's design, Euroz Hartleys said.It placed its forecasts, recommendation,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","BK7501","CYP.AU","LENZ","BK7067","BK7508","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644713380","title":"Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2644713380","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644713380?lang=en_us&edition=fundamental","pubTime":"2026-06-17 14:04","pubTimestamp":1781676270,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.The phase 1 results for CYP-001 were \"very positive,\" but the latest outcome fell \"well short of what we were hoping for,\" said Cynata CEO Kilian Kelly.The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7501","BK7508","BK7067","HST","BK4539","BK4585","BK4588","CYP.AU","BK4139","BK4181","LENZ","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230179","title":"BRIEF-Cynata Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230179?lang=en_us&edition=fundamental","pubTime":"2026-06-12 07:47","pubTimestamp":1781221657,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Seeks Trading Halt June 12 (Reuters) - Cynata Therapeutics Ltd CYP.AX:TRADING HALT PENDING PHASE 3 OSTEOARTHRITIS AND PHASE 2 GVHD TRIAL RESULTSFurther company coverage: CYP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642301242","title":"Cynata Therapeutics - Trading Halt Pending Phase 3 Osteoarthritis and Phase 2 Gvhd Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2642301242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642301242?lang=en_us&edition=fundamental","pubTime":"2026-06-12 07:47","pubTimestamp":1781221628,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CYP.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640217399","title":"Cynata Therapeutics Gets Positive European Opinion for Acute Graft Versus Host Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640217399","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640217399?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:45","pubTimestamp":1780443943,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  received a positive opinion from the European Medicines Agency's Paediatric Committee for a plan to develop its CYP-001 product candidate for the treatment of acute graft versus host disease, according to a Wednesday filing with the Australian bourse.The committee has agreed to the company's proposed pediatric investigation plan, which is a requirement to start a phase 3 clinical trial in the European Union.CYP-001 is designed for intravenous use to modulate the immune system and improve response rates and survival outcomes in acute graft versus host disease, an often life-threatening complication of bone marrow transplantation and similar procedures, per the filing.Cynata Therapeutics plans to launch a phase 3 clinical trial first in adults, and once the primary analysis of the adult trial is complete, it plans to start a pediatric clinical trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","CYP.AU","BK4181","BK7067","HST","BK4218","BK4007","BK7508","EPV","LENZ","BK4588","BK4585","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639612707","title":"Cynata Says WHO Selects Generic Name for Cymerus Mesenchymal Stem Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2639612707","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639612707?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:17","pubTimestamp":1780013828,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said the World Health Organization  selected pixenstrocel as the proposed generic name for Cymerus induced pluripotent stem cell -derived mesenchymal stem cells , according to a Friday Australian bourse filing.The proposed generic name is expected to be published in 2027 in the WHO Drug Information List 136 of Proposed International Nonproprietary Name, the company said. The final confirmation is expected around May 2027.The generic name represents the active agent in iPSC-derived MSC products.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK4150","MSC","BK4575","CYP.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639614139","title":"Cynata Therapeutics Ltd-Who Selects Proposed Inn for Cymerus Mscs","url":"https://stock-news.laohu8.com/highlight/detail?id=2639614139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639614139?lang=en_us&edition=fundamental","pubTime":"2026-05-29 06:56","pubTimestamp":1780008988,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUE7690PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638750785","title":"Cynata Therapeutics Says Results for Phase Three Drug Candidate Study for Knee Osteoarthritis Expected in June; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638750785","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638750785?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:02","pubTimestamp":1779858174,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said the results for the Australian phase three SCUlpTOR trial of its CYP-004 drug candidate in patients with osteoarthritis of the knee are expected in June, according to a Wednesday Australian bourse filing.The trial enrolled a total of 321 patients, who were randomized to receive either CYP-004 or placebo, with co-primary endpoints assessing change in pain and cartilage thickness, the filing said. The study database was locked, and the process of data analysis is ongoing.The results for the company's phase two trial of its CYP-001 drug candidate in adults with acute graft versus host disease are anticipated in late June or early July.A total of 65 participants were enrolled across clinical centers in Australia, the US, and Europe, randomized to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint is overall response rate at Day 28.The company's shares rose nearly 6% in recent trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK7501","BK7067","BK4139","BK4007","BK7508","LENZ","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476054","title":"Cynata Therapeutics' Upcoming Trial Readouts 'Most Significant Catalysts' in Years, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634476054?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:49","pubTimestamp":1778471358,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  continued to progress its clinical pipeline during the March quarter, and topline trial readouts due in the coming weeks represent \"the most significant catalysts\" for the company in several years, Euroz Hartleys said in a May 8 note.The company's lead phase two trial of CYP-001 in acute graft-versus-host disease is due for results in June. The therapy candidate \"could attract significant commercial interest\" if it replicates phase one results, which showed a roughly 86% overall response rate at day 28 compared with around 62% for standard of care, the equity research firm said.Meanwhile, topline results from a phase three trial of CYP-004 in osteoarthritis are expected in May, where a positive outcome would likely drive global partnering interest given the size of the osteoarthritis market and the potential for the drug candidate to become the first disease-modifying therapy for the indication, Euroz Hartleys said.Cynata Therapeutics' operating cash outflows are e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4539","BK7501","LENZ","BK4007","BK4139","CYP.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632006984","title":"Cynata Therapeutics Secures Commitments for AU$1.5 Million Share Placement; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632006984","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632006984?lang=en_us&edition=fundamental","pubTime":"2026-05-04 10:19","pubTimestamp":1777861183,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  received firm commitments for a placement of about 6 million ordinary shares priced at AU$0.25 each for gross proceeds of about AU$1.5 million, according to a Monday filing with the Australian bourse.The company plans to use the proceeds for potential commercial partnerships following the release of results for its osteoarthritis and acute graft-versus-host disease clinical trials expected in May and June, respectively.The \"strategically sized\" placement allows the company to bolster its cash runway beyond the readout of the results while minimizing dilution, it said.Cynata Therapeutics shares fell 4% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK7501","LENZ","BK4007","BK7067","BK4139","BK7508","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632798104","title":"BRIEF-Cynata Therapeutics Receives Commitments For A$1.5 Mln Placement At A$0.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632798104","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632798104?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:20","pubTimestamp":1777857636,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Receives Commitments For A$1.5 Mln Placement At A$0.25 Per ShareMay 4 (Reuters) - Cynata Therapeutics Ltd CYP.AX:RECEIVES COMMITMENTS FOR A$1.5 MILLION INSTITUTIONAL PLACEMENT AT A$0.25 PER SHAREFurther company coverage: CYP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41F00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632986092","title":"Cynata Therapeutics Ltd - Receives Commitments for a$1.5 Mln Institutional Placement at a$0.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632986092","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632986092?lang=en_us&edition=fundamental","pubTime":"2026-05-04 07:06","pubTimestamp":1777849560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nFWN41F00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CYP.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575156","title":"BRIEF-Cynata Therapeutics Seeks Trading Halt Pending Announcement On Proposed Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575156","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575156?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:03","pubTimestamp":1777507395,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Seeks Trading Halt Pending Announcement On Proposed Capital RaisingApril 30 (Reuters) - Cynata Therapeutics Ltd CYP.AX:CYNATA THERAPEUTICS LTD - TRADING HALT REQUESTED PENDIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41C1WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7508","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631784905","title":"Cynata Therapeutics Ltd - Trading Halt Requested Pending Announcement on Proposed Capital Raising via Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631784905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631784905?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:03","pubTimestamp":1777503798,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CYP.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623927367","title":"Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2623927367","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623927367?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:48","pubTimestamp":1774838890,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said the 100-day primary evaluation period was completed for the final participant enrolled in its phase two clinical trial of its CYP-001 drug candidate in adults with acute graft versus host disease, according to a Monday Australian bourse filing.A total of 65 participants were enrolled in the trial, and the participants were randomized to receive either steroids plus CYP-001 or steroids plus placebo.The primary endpoint is the overall response rate at day 28, and results are anticipated in June.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CYP.AU","BK4218","BK4585","BK7067","BK7508","LENZ","BK4539","BK4007","BK4139","BK4588","BK4181","BK7501","HST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","CYP.AU","BK4007","BK4539","LENZ","BK7067","MSB.AU","BK4139","MESO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}